Summary Liver transplant (ation)(LT) is the most effective treatment for patients with
decompensated liver disease. The increasing prevalence of obesity and type 2 diabetes and …

Cardiac diseases are one of the most common causes of morbidity and mortality following
liver transplantation (LT). Prior studies have shown that cardiac diseases affect close to one …

Background: The high prevalence of obesity in the United States drives the burden of NASH,
recently renamed as metabolic dysfunction–associated steatohepatitis (MASH). We …

The prevalence and mortality related to end-stage liver disease (ESLD) continue to rise
globally. Liver transplant (LT) recipients continue to be older and have inherently more …

Tacrolimus (TAC) is a dose‐dependent immunosuppressor with considerable intrapatient
variability (IPV) in its pharmacokinetics. The aim of this work is to ascertain the association …

Post-transplant metabolic syndrome (PTMS) has been associated with increased
cardiovascular risk which significantly impacts the morbidity and mortality rates of liver …

Introduction Dietary modification and exercise are encouraged to address cardiometabolic
risk factors after solid organ transplantation. However, the lived experience of attempting …

While outcomes after liver transplantation have increased over the last two decades, this is
primarily as a consequence of a reduction in early deaths and survival of those who survive …

Background Liver transplant recipients are prone to both short-term and long-term
complications and may present to any emergency department. Objective This narrative …

Cardiovascular diseases are currently one of the most important causes of morbidity and
mortality in liver transplant patients over the long term. Therefore, evaluating prognostic …